Related Experiment Video
Updated: Jun 23, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Hematology: Bortezomib in newly diagnosed multiple myeloma
1Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA. jberenson@myelomasource.org
Abstract:
Preclinical studies have shown that new agents such as bortezomib not only demonstrate anti-multiple-myeloma activity as single agents but also enhance the efficacy of both chemotherapy and steroids. A randomized trial has established that bortezomib not only improves response rates but also prolongs the lives of patients with multiple myeloma who are not candidates for high-dose chemotherapy.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Treatment Resistent Cancers
Treatment Resistant Cancers
